文献速递淋巴瘤白血病

基于BET蛋白降解靶向嵌合体的Richter转化弥漫大B细胞淋巴瘤新型模型治疗研究

BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
PubMed 文献 · Leukemia · 2021-03-02

研究建立了三株Richter转化弥漫大B细胞淋巴瘤(RT-DLBCL)患者来源异种移植(PDX)模型,涵盖克隆相关(CLR)与克隆无关(CLUR)类型。模型显示IRF4、TCF4、BCL2高表达及BET抑制剂敏感性,BET-PROTAC与venetoclax联用可显著降低淋巴瘤负荷并改善免疫缺陷小鼠生存。

要点

  • RT-DLBCL的PDX模型显示IRF4、TCF4、BCL2表达升高及BET抑制剂敏感性。
  • BET抑制剂或BET-PROTAC与ibrutinib或venetoclax联用具体外协同致死作用。
  • BET-PROTAC联合venetoclax在CLR-RT-DLBCL小鼠模型中降低瘤负荷并改善生存。

核心结论

  • BET-PROTAC联合venetoclax是RT-DLBCL潜在有效的新型治疗策略。

研究设计与样本

  • 研究建立三株RT-DLBCL患者来源异种移植(PDX)模型,包括克隆相关(CLR)与克隆无关(CLUR)类型。
  • 对模型进行遗传变异、染色质可及性、活性增强子、基因表达及抗淋巴瘤药物敏感性分析。
  • 在免疫缺陷小鼠中进行BET-PROTAC与venetoclax联合治疗实验。

主要发现

  • CLR与CLUR RT-DLBCL细胞显示活性增强子、单细胞RNA测序mRNA及IRF4、TCF4、BCL2蛋白表达升高。
  • RT-DLBCL细胞对BET蛋白抑制剂敏感性增加。
  • CRISPR敲除IRF4减弱c-Myc水平并增加对BET蛋白抑制剂的敏感性。
  • BET抑制剂或BET-PROTAC与ibrutinib或venetoclax联用在RT-DLBCL细胞中产生体外协同致死作用。
  • BET-PROTAC联合venetoclax较单药显著降低CLR-RT-DLBCL小鼠淋巴瘤负荷并改善生存。

临床怎么用

  • BET-PROTAC联合venetoclax可能作为RT-DLBCL的候选治疗策略。
  • IRF4高表达及BET抑制剂敏感性可作为潜在生物标志物方向。

局限性

  • 研究基于PDX模型及免疫缺陷小鼠,尚未在临床试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Richter Transformation (RT) develops in CLL as an aggressive, therapy-resistant, diffuse large B cell lymphoma (RT-DLBCL), commonly clonally-related (CLR) to the concomitant CLL. Lack of available pre-clinical human models has hampered the development of novel therapies for RT-DLBCL. Here, we report the profiles of genetic alterations, chromatin accessibility and active enhancers, gene-expressions and anti-lymphoma drug-sensitivity of three newly established, patient-derived, xenograft (PDX) models of RT-DLBCLs, including CLR and clonally-unrelated (CLUR) to concomitant CLL. The CLR and CLUR RT-DLBCL cells display active enhancers, higher single-cell RNA-Seq-determined mRNA, and protein expressions of IRF4, TCF4, and BCL2, as well as increased sensitivity to BET protein inhibitors. CRISPR knockout of IRF4 attenuated c-Myc levels and increased sensitivity to a BET protein inhibitor. Co-treatment with BET inhibitor or BET-PROTAC and ibrutinib or venetoclax exerted synergistic in vitro lethality in the RT-DLBCL cells. Finally, as compared to each agent alone, combination therapy with BET-PROTAC and venetoclax significantly reduced lymphoma burden and improved survival of immune-depleted mice engrafted with CLR-RT-DLBCL. These findings highlight a novel, potentially effective therapy for RT-DLBCL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Fiskus W, Mill CP, Perera D, et al. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia. 2021. PMID: 33654205. doi:10.1038/s41375-021-01181-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。